By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Gamida Cell Ltd. 

Harey Yehuda 54
P.O.B. 94
Savyon    56530  Israel
Phone: 03-534-7482 Fax: 03-534-3067



Company News
Gamida Cell Achieves Major Regulatory Milestone: FDA And European Medicines Agency Respond Positively to NiCord Phase III Study Design Outline 8/10/2015 6:13:08 AM
Runaway Bride Novartis AG (NVS) Leaves Gamida Cell At the Altar for Second Time, Will Pay $142M Breakup Fee 6/3/2015 6:34:35 AM
First Patient Successfully Transplanted With Cryopreserved (Frozen) Nicord® In Gamida Cell Ltd.'s Ongoing Phase I/II Clinical Trial For Blood Cancers 1/8/2015 8:10:22 AM
Gamida Cell Ltd.'s NiCord® Receives FDA And European Medicines Agency Orphan Drug Designation 1/6/2015 10:54:48 AM
Confirmed: Novartis AG (NVS) To Invest In Gamida Cell Ltd., Could Buy Out Company In $635 Million Cancer Deal 8/19/2014 6:22:36 AM
Deal Is Back On: Novartis AG (NVS) To Invest Heavily In Gamida Cell Ltd. Before Acquisition 8/18/2014 6:05:49 AM
Novartis AG (NVS) Abandons $600 Million Purchase Of Gamida Cell Ltd. 5/2/2014 8:35:18 AM
Gamida Cell Ltd. Gets Hefty Buyout Offer From Unknown Global Pharma Co., Is It Novartis AG (NVS)? 3/18/2014 7:39:06 AM
Gamida Cell Ltd. Announces the Successful Transplantation of the First Patient in the Company's Phase I/II Study of NiCord® in a Single Cord Configuration 9/9/2013 10:11:57 AM
Gamida Cell Ltd. Reports FDA Recommending Further Study of StemEx® 7/1/2013 7:57:10 AM